BRPI0108395B8 - derivados de pirrolopirimidinona, processos de preparação e uso - Google Patents

derivados de pirrolopirimidinona, processos de preparação e uso

Info

Publication number
BRPI0108395B8
BRPI0108395B8 BRPI0108395A BR0108395A BRPI0108395B8 BR PI0108395 B8 BRPI0108395 B8 BR PI0108395B8 BR PI0108395 A BRPI0108395 A BR PI0108395A BR 0108395 A BR0108395 A BR 0108395A BR PI0108395 B8 BRPI0108395 B8 BR PI0108395B8
Authority
BR
Brazil
Prior art keywords
preparation
use processes
pyrrolopyrimidinone derivatives
pyrrolopyrimidinone
derivatives
Prior art date
Application number
BRPI0108395A
Other languages
English (en)
Other versions
BR0108395A (pt
BRPI0108395B1 (pt
Inventor
Kim Dae-Kee
Hyun Ryu Do
Im Guang-Jin
Cha Hoon
Kim Jae-Sum
Ho Ryu Je
Choi Jin-Young
Young Lee Ju
Kyu Lee Nam
Kim Nam-Ho
Ho Lee Suk
Kon Kim Tae
Choi Won-Son
Original Assignee
In2Gen Co Ltd
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In2Gen Co Ltd, Sk Chemicals Co Ltd filed Critical In2Gen Co Ltd
Publication of BR0108395A publication Critical patent/BR0108395A/pt
Publication of BRPI0108395B1 publication Critical patent/BRPI0108395B1/pt
Publication of BRPI0108395B8 publication Critical patent/BRPI0108395B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

"derivados de pirrolopirimidinona, processos de preparação e uso". a invenção se refere a uma série de derivados de pirrolopirimidinona da fórmula (1), processos para a preparação dos mesmos, intermediários na preparação dos mesmos, uso dos mesmos como agentes terapêuticos e composições farmacêuticas contendo os mesmos.
BRPI0108395A 2000-02-17 2001-02-15 derivados de pirrolopirimidinona, processos de preparação e uso BRPI0108395B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000007625A KR100358083B1 (ko) 2000-02-17 2000-02-17 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
PCT/KR2001/000227 WO2001060825A1 (en) 2000-02-17 2001-02-15 Pyrrolopyrimidinone derivatives, process of preparation and use

Publications (3)

Publication Number Publication Date
BR0108395A BR0108395A (pt) 2003-03-11
BRPI0108395B1 BRPI0108395B1 (pt) 2017-06-06
BRPI0108395B8 true BRPI0108395B8 (pt) 2021-05-25

Family

ID=19647449

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108395A BRPI0108395B8 (pt) 2000-02-17 2001-02-15 derivados de pirrolopirimidinona, processos de preparação e uso

Country Status (23)

Country Link
US (1) US6962911B2 (pt)
EP (1) EP1257553B1 (pt)
JP (1) JP4845076B2 (pt)
KR (1) KR100358083B1 (pt)
CN (1) CN1312153C (pt)
AT (1) ATE267829T1 (pt)
AU (2) AU3614001A (pt)
BR (1) BRPI0108395B8 (pt)
CA (1) CA2400268C (pt)
DE (1) DE60103508T2 (pt)
DK (1) DK1257553T3 (pt)
ES (1) ES2222344T3 (pt)
HU (1) HU230344B1 (pt)
IL (2) IL151234A0 (pt)
MX (1) MXPA02007942A (pt)
NO (1) NO323553B1 (pt)
NZ (1) NZ520842A (pt)
PL (1) PL210796B1 (pt)
PT (1) PT1257553E (pt)
RU (1) RU2263676C2 (pt)
TR (1) TR200402101T4 (pt)
WO (1) WO2001060825A1 (pt)
ZA (1) ZA200206587B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
EP1362858A1 (en) * 2002-05-15 2003-11-19 SK Chemicals Co., Ltd. Pyrrolopyrimidinone derivates, process of preparation and use
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
AR058071A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas.
US20100069632A1 (en) * 2006-07-03 2010-03-18 Sk Chemicals Co., Ltd Salts of pyrrolopyrimidinone derivatives and process for preparing the same
KR20080003599A (ko) * 2006-07-03 2008-01-08 에스케이케미칼주식회사 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
DK2488525T3 (en) 2009-10-16 2018-08-06 Melinta Therapeutics Inc ANTIMICROBIAL COMPOUNDS AND PROCEDURES FOR PREPARING AND USING THEREOF
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
KR20180069098A (ko) 2009-10-16 2018-06-22 멜린타 테라퓨틱스, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
KR101377178B1 (ko) 2010-04-05 2014-03-26 에스케이케미칼주식회사 Ｐｄｅ5 억제제를 함유하는 피부 주름 개선용 조성물
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
TWI490220B (zh) * 2011-04-04 2015-07-01 Sk Chemicals Co Ltd 包含ｐｄｅ５抑制劑之用於減少皮膚皺紋之組成物
EA201391536A1 (ru) 2011-04-15 2014-08-29 Мелинта Терапьютикс, Инк. Противомикробные соединения и способы их получения и применения
WO2013036081A2 (en) * 2011-09-09 2013-03-14 Sk Chemicals Co., Ltd. Composition for reducing skin wrinkles including pde5 inhibitor
CN105025900B (zh) 2012-12-04 2018-11-02 株式会社阿丽浱欧 包含5型磷酸二酯酶抑制剂的神经细胞的细胞凋亡抑制用组合物
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
SG11201707346RA (en) 2015-03-11 2017-10-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
CN104744478B (zh) * 2015-03-20 2016-08-24 中国人民解放军第二军医大学 一种防治辐射损伤的化合物、单晶及其制备方法和应用
SI3377495T1 (sl) * 2015-11-16 2022-06-30 Topadur Pharma Ag 2-fenil-3,4-dehidropirolo(2,1-F)(1,2,4)triazinonski derivati kot zaviralci fosfodiesteraze in uporaba le-teh
EP3452479A1 (en) 2016-05-06 2019-03-13 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
JP7182568B2 (ja) * 2017-05-22 2022-12-02 トパドゥール ファーマ アーゲー 新規二重作用モード可溶性グアニル酸シクラーゼ活性化因子およびホスホジエステラーゼ阻害剤ならびにその使用
AU2019319004A1 (en) 2018-08-06 2021-03-25 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
AU2019389263A1 (en) 2018-11-28 2021-06-03 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN111825593B (zh) * 2020-08-19 2023-04-07 上海成澄科技有限公司 3-氨基吡咯-2-甲酰胺类化合物的合成方法
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
JP2024536047A (ja) 2021-09-29 2024-10-04 トパデュール ファルマ アーゲー ２－フェニル－３，４－ジヒドロピロロ［２，ｌ－ｆ］［１，２，４］トリアジノン誘導体の局所組成物及びその使用
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
WO2023166013A1 (en) 2022-03-02 2023-09-07 Topadur Pharma Ag Topical compositions and uses therof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5761734B2 (pt) * 1973-09-27 1982-12-25 Takeda Chemical Industries Ltd
JPS5761734A (en) * 1980-10-02 1982-04-14 Teijin Ltd Spun like fabric
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) * 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
SK285991B6 (sk) * 1997-04-25 2008-01-07 Pfizer Inc. Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
EA200000969A1 (ru) * 1998-04-20 2001-06-25 Пфайзер Инк. ИНГИБИТОРЫ цГМБ ФДЭ5 НА ОСНОВЕ ПИРАЗОЛПИРИМИДИНОНА ДЛЯ ЛЕЧЕНИЯ ПОЛОВЫХ ДИСФУНКЦИЙ
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도

Also Published As

Publication number Publication date
US20030171361A1 (en) 2003-09-11
PL358188A1 (en) 2004-08-09
RU2002124872A (ru) 2004-01-10
KR100358083B1 (ko) 2002-10-25
NZ520842A (en) 2004-04-30
BR0108395A (pt) 2003-03-11
IL151234A (en) 2010-05-17
JP4845076B2 (ja) 2011-12-28
DK1257553T3 (da) 2004-10-04
WO2001060825A1 (en) 2001-08-23
NO323553B1 (no) 2007-06-11
EP1257553A1 (en) 2002-11-20
US6962911B2 (en) 2005-11-08
IL151234A0 (en) 2003-04-10
DE60103508D1 (de) 2004-07-01
DE60103508T2 (de) 2005-06-30
PL210796B1 (pl) 2012-03-30
AU2001236140B9 (en) 2006-08-31
EP1257553B1 (en) 2004-05-26
NO20023823D0 (no) 2002-08-13
CA2400268C (en) 2009-08-18
RU2263676C2 (ru) 2005-11-10
TR200402101T4 (tr) 2004-10-21
KR20010083637A (ko) 2001-09-01
ATE267829T1 (de) 2004-06-15
HUP0300527A2 (hu) 2003-07-28
JP2003523344A (ja) 2003-08-05
AU3614001A (en) 2001-08-27
BRPI0108395B1 (pt) 2017-06-06
ZA200206587B (en) 2003-10-09
AU2001236140B2 (en) 2006-01-12
HUP0300527A3 (en) 2012-10-29
CN1312153C (zh) 2007-04-25
HU230344B1 (hu) 2016-02-29
ES2222344T3 (es) 2005-02-01
NO20023823L (no) 2002-10-09
CN1422271A (zh) 2003-06-04
MXPA02007942A (es) 2004-09-10
CA2400268A1 (en) 2001-08-23
PT1257553E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
SE9904505D0 (sv) Novel compounds
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
MXPA03005464A (es) Agentes antivirales.
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
PT1263725E (pt) Novos compostos
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
IS6658A (is) Ný efnasambönd
SE0102616D0 (sv) Novel compounds
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
SE0100569D0 (sv) New compounds
BR0111678A (pt) Composições medicinais contendo derivados de propenona
NO20020282L (no) Nytt difenyl-piperidinderivat
SE0102055D0 (sv) New Compounds
DE69819539D1 (de) Antithrombotische mittel
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
PA8509601A1 (es) "PIRAZOLO [4,3,e] DIAZEPINAS SUSTITUIDAS NOVEDOSAS, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN, SU USO COMO PRODUCTOS MEDICINALES Y PROCESOS PARA PREPARARLAS
ATE286395T1 (de) Antithrombotische mittel
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. C07D 487/04, A61K 31/519, C07D 207/34, A61P 9/00

Ipc: C07D 487/04 (2006.01), A61K 31/519 (2006.01), C07D

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/02/2021